This practice is called off-label use. How Mounjaro Works and Why That Matters for Safety Mounjaro works by targeting two hormone receptors, GIP and GLP-1, simultaneously
It upregulates growth factors including VEGF and EGF
At the end of the 12-month intervention, the prescribing rate increased to 37.9% (2,797/7,374) in VAAAHS, 28.4% (16,605/58,525) in the VISN 10 region, and 26.5% (173,837/654,994) in VA nationally
With a few months between Phase I and II, it can take as much as 5 years to get from application to the end of a successful Phase II these are not small projects or commitments
Medical weight loss intervention has been skyrocketing in recent years with many drugs on the market or in clinical trials, including incretin memetics or incretin receptor agonists such as Ozempic (semaglutide, SEMA) targeting glucagon-like peptide-1 (GLP-1) receptor (GLP1R) or dual agonist Mounjaro (tirzepatide) targeting GLP1R and glucose-dependent insulinotropic polypeptide (GIP) receptor (GIPR)